Long-term recombinant FGF-21 therapy lowers hepatic and serum triglyceride levels and decreases the fattiness of the liver in mice with diet-induced obesity; these actions may occur through suppression of SREBP1, a lipogenic gene [64]. The gene discussed is SREBF1; the disease is Obesity.